Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics.
10.3785/j.issn.1008-9292.2020.04.04
- Author:
Chunlin WANG
1
;
Li LIANG
1
Author Information
1. Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Aromatase Inhibitors;
therapeutic use;
Child;
Estrogens;
Humans;
Male;
Puberty, Precocious
- From:
Journal of Zhejiang University. Medical sciences
2020;49(3):275-282
- CountryChina
- Language:Chinese
-
Abstract:
Aromatase is the rate-limiting enzyme in estrogen biosynthesis. The third generation aromatase inhibitors (AIs), represented by letrozoleand and anastrozole, can combine with aromatase, effectively reducing the estrogen level in the body. Because of its high efficiency, selectivity and reversibility, it has been used in the treatment of McCune-Albright syndrome, familial male-limited precocious puberty, gynecomastia, and adolescent boy with short stature. The good efficacy and safety of AIs have been observed. However, so far the drug instructions of AIs usually do not show indications for children; there are risks of adverse reactions involving liver and kidney function, lipid metabolism, hyperandrogenemia and bone metabolism; especially the long-term effects on reproductive system and bone metabolism are still not clear. Therefore, it is necessary to prescribe it carefully and follow up closely. It was not recommended that AIs be routinely used to improve adult height of adolescent boy with short stature. And more clinical evidences are needed for the safety and effectiveness of AIs prescribed in pediatrics.
